1:41 PM
 | 
Jan 03, 2018
 |  BC Extra  |  Company News

Array grants Aslan full rights to varlitinib

Array BioPharma Inc. (NASDAQ:ARRY) granted Aslan Pharmaceuticals Ltd. (TPEx:6497) exclusive, worldwide rights to develop and commercialize cancer candidate varlitinib (ASLAN001). The new deal replaces a 2011 deal in which Aslan received rights only to develop and sublicense, but not commercialize, the oral small molecule inhibitor of EGFR (ErbB1; HER1), HER2,...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >